Tiziana Life Sciences posts 2025 interim results update

Tiziana Life Sciences LTD submitted a Form 6-K to furnish its interim financial results for the six months ended June 30, 2025 and to provide a corporate update on its lead development programs.

Rhea-AI Filing Summary

Tiziana Life Sciences LTD submitted a Form 6-K to furnish its interim financial results for the six months ended June 30, 2025 and to provide a corporate update on its lead development programs. These details are contained in an accompanying announcement labeled Exhibit 99.1. The information in that exhibit is treated as furnished rather than filed under U.S. securities laws, which affects how related legal liabilities apply. The company also states that this Form 6-K, including Exhibit 99.1, is incorporated by reference into its existing shelf registration statement on Form F-3, allowing the interim results and corporate update to be part of the disclosure package for any future securities offerings under that registration.

FAQ

What did Tiziana Life Sciences (TLSA) disclose in this Form 6-K?

Tiziana Life Sciences LTD furnished a Form 6-K to present its interim financial results for the six months ended June 30, 2025 and to provide a corporate update on its lead programs in development. This information is contained in an announcement attached as Exhibit 99.1.

Which period do Tiziana Life Sciences (TLSA) interim results cover in this filing?

The interim results disclosed by Tiziana Life Sciences LTD in this Form 6-K cover the six-month period ended June 30, 2025, as stated in the description of the announcement furnished as Exhibit 99.1.

How is the information in Exhibit 99.1 to the TLSA Form 6-K treated under U.S. securities law?

The company states that the information in Exhibit 99.1 is being furnished and is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, and it is not subject to the liabilities of that Section, unless later specifically incorporated by reference.

Is the October 3, 2025 Tiziana Life Sciences (TLSA) Form 6-K linked to any registration statement?

Yes. The company explains that this Form 6-K, including Exhibit 99.1, is incorporated by reference into its Registration Statement on Form F-3 with registration number 333-286064 filed on March 24, 2025.

Who signed the October 3, 2025 Tiziana Life Sciences (TLSA) Form 6-K?

The Form 6-K was signed on behalf of Tiziana Life Sciences LTD by Keeren Shah, who is identified in the document as the Chief Financial Officer.

What is Exhibit 99.1 in the Tiziana Life Sciences (TLSA) Form 6-K?

Exhibit 99.1 is described as "Tiziana Life Sciences LTD Interim Results and Update, dated October 3, 2025," which contains the interim financial results and corporate update referenced in the body of the Form 6-K.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/03/2025 - 04:30 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

October 2025

Commission File Number:  001-38723

Tiziana Life Sciences LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒           Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On October 3, 2025, Tiziana Life Sciences LTD (the “Company”) issued this 6K filing its interim financial results for the six months ended June 30, 2025, and provided a corporate update on its lead programs in development.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

This report on Form 6-K, including Exhibit 99.1 is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (Reg. No. 333-286064) filed with the SEC on March 24, 2025.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TIZIANA LIFE SCIENCES LTD
Date: October 3, 2025	By:	/s/ Keeren Shah
		Name:	Keeren Shah
		Title:	Chief Financial Officer

2

EXHIBIT INDEX

Exhibit No.		Description
99.1		Tiziana Life Sciences LTD Interim Results and Update, dated October 3, 2025

3